CTRI/2023/10/058324招募中3 期
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants with Type 2 Diabetes Mellitus who have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-2) - NI
Eli Lilly and Company India Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Have a body mass index (BMI) greater than or equal to 27.0 kilogram/square meter (kg/m²)
- •2. Have Type 2 Diabetes (T2D)
- •3. Are on stable treatment for T2D for at least 90 days
- •4. Have a history of at least one unsuccessful dietary effort to lose body weight
排除标准
- •1. Have a self-reported or documented change in body weight >5 kg (11 pounds) within 90 days
- •2. Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening
- •3. Have a prior or planned surgical treatment for obesity
- •4. Have Type 1 diabetes.
- •5. Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
- •6. Have had pancreatitis
研究者
相似试验
进行中（未招募）
1 期
A Study in Patients with Obesity and Obstructive Sleep ApneaEUCTR2021-004551-16-CZEli Lilly and Company206
尚未招募
3 期
A Study of LY3437943 in Obese or Overweight PatientsCTRI/2023/11/059873Eli Lilly and Company India Pvt Ltd
进行中（未招募）
1 期
A Study in Patients with Obesity and Obstructive Sleep ApneaEUCTR2021-004552-41-CZEli Lilly and Company206
进行中（未招募）
3 期
The purpose of this study is to evaluate the effect and safety of tirzepatide in participants with obstructive sleep apnea and obesity who are and plan to stay on PAP therapy in GPI-2JPRN-jRCT2031220155Masaki Takeshi206
进行中（未招募）
3 期
The purpose of this study is to evaluate the effect and safety of tirzepatide in participants with obstructive sleep apnea and obesity who are both unwilling or unable to use Positive Airway Pressure (PAP) therapy in GPI-1JPRN-jRCT2031220154Masaki Takeshi206